Induction of pancreatic ?-cell proliferation by pharmacological inhibitors of DYRK1A kinase, an innovative regenerative approach for the treatment of diabetes – KINHIB-DIAB
The loss of functional ? cells is the root cause for the development of diabetes. Therapies aimed at the replenishment of the pancreatic ? cell are among the most promising strategies to treat diabetes. In this project, we will investigate the effects of new selective Dyrk1A inhibitors developed by a French Biotech, on the proliferation of human ? cells, and the regeneration of ? cell in relevant preclinical models of type 2 diabetes. This translational research program will pave the way for the rapid clinical evaluation of these highly advanced Dyrk1A inhibitors in diabetic patients.
Project coordination
Jamileh Movassat (Unité de biologie fonctionnelle et adaptative)
The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.
Partnership
LCBPT Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques
PERHA PHARMACEUTICALS
BFA Unité de biologie fonctionnelle et adaptative
HIPI Immunologie Humaine, Pathophysiologie, Immunothérapie
Help of the ANR 616,338 euros
Beginning and duration of the scientific project:
January 2023
- 48 Months
